COVID-19: A Worldwide Gene Polymorphism
Journal of Cellular & Molecular Anesthesia,
Vol. 8 No. 3 (2023),
14 July 2023
,
Page 139-140
https://doi.org/10.22037/jcma.v8i3.42699
Abstract
Keywords:
- COVID-19
- Gene Polymorphism
How to Cite
1.
Roodneshin F. COVID-19: A Worldwide Gene Polymorphism. J Cell Mol Anesth [Internet]. 2023 Jul. 14 [cited 2025 Jan. 13];8(3):139-40. Available from: https://journals.sbmu.ac.ir/jcma/article/view/42699
References
1. Dabbagh A. Cellular and Molecular Approaches to COVID-19: “Road to Perdition” or “The Shawshank Redemption”. J Cell Mol Anesth. 2020;5(4):214.
2. Pourhossein B, Dabbagh A, Fazeli M. Insights into the SARS-CoV2 Outbreak; the Great Global Challenge: A Mini Review. J Cell Mol Anesth. 2020;5(1):23-6.
3. Dabbagh A. COVID-19: Apocalypse Now? J Cell Mol Anesth. 2020;5(1):1-2.
4. Dorgalaleh A, Dabbagh A, Tabibian S, Baghaeipour MR, Jazebi M, Bahraini M, et al. Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)? Semin Thromb Hemost. 2020;46(7):853-5.
5. Safari S, Salimi A, Zali A, Jahangirifard A, Bastanhagh E, Aminnejad R, et al. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review. Arch Acad Emerg Med. 2020;8(1):e67.
6. Rajaei S, Dabbagh A. The immunologic basis of COVID-19: a clinical approach. J Cell Mol Anesth. 2020;5(1):37-42.
7. Gupta P, Mohapatra E, Patel S, Patnayak LL, Nanda R, Shah S, et al. Effect of the Angiotensin-Converting Enzyme (ACE) (I/D) Polymorphism in COVID-19 Patients and Their Healthy Contacts. Cureus. 2023;15(5):e38610.
8. Mir MM, Mir R, Alghamdi MAA, Alsayed BA, Wani JI, Alharthi MH, et al. Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality. J Pers Med. 2021;11(11).
9. Sarangarajan R, Winn R, Kiebish MA, Bountra C, Granger E, Narain NR. Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. J Racial Ethn Health Disparities. 2021;8(4):973-80.
10. Aziz MA, Islam MS. Association of ACE1 I/D rs1799752 and ACE2 rs2285666 polymorphisms with the infection and severity of COVID-19: A meta-analysis. Mol Genet Genomic Med. 2022;10(11):e2063.
11. Karimi FH, V. Ahmadi, A. Ranjbar Kermani, F. Ferdowsi, S. The Evaluation of ACE1-I/D Polymorphism in Kurdish Patients With Severe COVID-19. J Cell Mol Anesth. 2023;8(3):141-9.
12. Delanghe JR, De Buyzere ML, Speeckaert MM. Genetic Polymorphisms in the Host and COVID-19 Infection. Adv Exp Med Biol. 2021;1318:109-18.
13. Verma S, Abbas M, Verma S, Khan FH, Raza ST, Siddiqi Z, et al. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021;91:104801.
14. Dieter C, Brondani LA, Leitão CB, Gerchman F, Lemos NE, Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. PLoS One. 2022;17(7):e0270627.
15. Sezari P, Dabbagh A. Personalized medicine: the paradigm shift in medicine mandating lifelong learning. J Cell Mol Anesth. 2019;4(2):31-2.
2. Pourhossein B, Dabbagh A, Fazeli M. Insights into the SARS-CoV2 Outbreak; the Great Global Challenge: A Mini Review. J Cell Mol Anesth. 2020;5(1):23-6.
3. Dabbagh A. COVID-19: Apocalypse Now? J Cell Mol Anesth. 2020;5(1):1-2.
4. Dorgalaleh A, Dabbagh A, Tabibian S, Baghaeipour MR, Jazebi M, Bahraini M, et al. Patients with Congenital Bleeding Disorders Appear to be Less Severely Affected by SARS-CoV-2: Is Inherited Hypocoagulability Overcoming Acquired Hypercoagulability of Coronavirus Disease 2019 (COVID-19)? Semin Thromb Hemost. 2020;46(7):853-5.
5. Safari S, Salimi A, Zali A, Jahangirifard A, Bastanhagh E, Aminnejad R, et al. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review. Arch Acad Emerg Med. 2020;8(1):e67.
6. Rajaei S, Dabbagh A. The immunologic basis of COVID-19: a clinical approach. J Cell Mol Anesth. 2020;5(1):37-42.
7. Gupta P, Mohapatra E, Patel S, Patnayak LL, Nanda R, Shah S, et al. Effect of the Angiotensin-Converting Enzyme (ACE) (I/D) Polymorphism in COVID-19 Patients and Their Healthy Contacts. Cureus. 2023;15(5):e38610.
8. Mir MM, Mir R, Alghamdi MAA, Alsayed BA, Wani JI, Alharthi MH, et al. Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality. J Pers Med. 2021;11(11).
9. Sarangarajan R, Winn R, Kiebish MA, Bountra C, Granger E, Narain NR. Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. J Racial Ethn Health Disparities. 2021;8(4):973-80.
10. Aziz MA, Islam MS. Association of ACE1 I/D rs1799752 and ACE2 rs2285666 polymorphisms with the infection and severity of COVID-19: A meta-analysis. Mol Genet Genomic Med. 2022;10(11):e2063.
11. Karimi FH, V. Ahmadi, A. Ranjbar Kermani, F. Ferdowsi, S. The Evaluation of ACE1-I/D Polymorphism in Kurdish Patients With Severe COVID-19. J Cell Mol Anesth. 2023;8(3):141-9.
12. Delanghe JR, De Buyzere ML, Speeckaert MM. Genetic Polymorphisms in the Host and COVID-19 Infection. Adv Exp Med Biol. 2021;1318:109-18.
13. Verma S, Abbas M, Verma S, Khan FH, Raza ST, Siddiqi Z, et al. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021;91:104801.
14. Dieter C, Brondani LA, Leitão CB, Gerchman F, Lemos NE, Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. PLoS One. 2022;17(7):e0270627.
15. Sezari P, Dabbagh A. Personalized medicine: the paradigm shift in medicine mandating lifelong learning. J Cell Mol Anesth. 2019;4(2):31-2.
- Abstract Viewed: 114 times
- PDF Downloaded: 83 times